Some with Alzheimer's better off staying on antipsychotics, study reports
Agitation, aggression more likely to return in those who stopped taking Risperdal, research shows.
(HealthDay)—People with Alzheimer's disease who take the antipsychotic drug risperidone (Risperdal) to help curb their agitation and aggression may see a return of these troublesome symptoms if they stop taking the medication, a new study suggests.
Not every person with Alzheimer's will become agitated and/or aggressive, but among those who do, these symptoms make it difficult for caregivers to manage them at home and often lead to nursing home admission and an increased risk of dying from the disease.
As it stands, these antipsychotic drugs are only supposed to be taken for three to six months due to concerns about side effects including weight gain, tremors and movement difficulty. In recent years, the U.S. Food and Drug Administration also placed a black-box warning on this class of medications warning that people with dementia who take antipsychotics have a higher risk of dying.
"Caregivers should be aware of the increased mortality associated with these medications in people with dementia," said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. However, he added, "if a patient is taking an antipsychotic and doing reasonably well without any major side effects, they should stay on it."
The new study, which appears in the Oct. 18 issue of the New England Journal of Medicine, sought to determine what happens when the medication is stopped among people who are doing well on it. The U.S. National Institutes of Health sponsored the trial.
Nursing home staff are tasked with providing written explanations if they choose to keep someone on one of these medications for longer than three to six months, Devanand noted. "One must be cautious about discontinuing the medication. If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely," he said.
Stopping treatment resulted in a relapse of symptoms for those who had been doing well on the medication for four to eight months, the investigators found.
The new study included 180 patients with Alzheimer's disease who showed signs of agitation and aggression. The patients, from eight U.S. centers, all received risperidone for 16 weeks in the first phase of the study. After that, the 110 patients who did well on the drug were assigned to take either risperidone or an inactive placebo. Those who were switched to a placebo were twice as likely to relapse when compared to participants who continued taking risperidone, the study found. What's more, the rate of side effects and death did not differ among participants.
Dr. Gary Kennedy, director of the division of geriatric psychiatry at Montefiore Medical Center in New York City, said that deciding how long to keep a person with Alzheimer's on an antipsychotic drug isn't an easy decision to make.
But "if a person is responding to the drug, it makes sense to stick with it," said Kennedy, who was not involved with the study.
Treating agitation and aggression in someone with Alzheimer's can make a big difference for the patient and the caregiver, he added. "These patients can be dangerous and very difficult to care for," Kennedy noted. "This is a very important study."
More information: Learn more about agitation among people with Alzheimer's disease at the Alzheimer's Association.
Journal reference: New England Journal of Medicine
Copyright © 2012 HealthDay. All rights reserved.
- Antipsychotic drugs double risk of death among Alzheimer's patients Jan 09, 2009 | not rated yet | 0
- Drug class not effective for Alzheimer's Oct 12, 2006 | not rated yet | 0
- Specific antipsychotic drugs increase risk of death in elderly dementia patients Feb 23, 2012 | not rated yet | 0
- Studies look at how genes affect antipsychotic drug response Nov 09, 2006 | not rated yet | 0
- Alzheimer's drug fails to reduce significant agitation May 02, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
question on coriolis effect with drag force
52 minutes ago I really need help with this question. A small floating object initially moves with velocity v on the surface of a liquid at latitude λ. The...
Question of reflection and transmission of TEM wave in normal incidenc
6 hours ago Suppose TEM wave in +z normal to a boundary on xy plane at z=0. We know *E* & *H* are tangential to the boundary. Let ##\vec E_i=\hat x E##, be the...
the rudyak-krasnolutski effective potencial
7 hours ago Hi ... anyone now how to calculate or the formula of the rudyak-krasnolutski EFFECTIVE potencial ? the effective potencial includes the angular...
Normal force for a lever model
8 hours ago My model is a lever on a table top. One arm is horizontal on the table, while the other arm is raised at an angle alpha. I'm assuming the weight of...
gravity is std. therefore can we rate a 'mass at height' by watts?
13 hours ago For example.... wind turbines are primarily listed by their wattage (1.5MW etc.) Presumably their output is varied according to rotational speed, so...
Calculating on-axis elements of a solenoid
May 22, 2013 I wanted to mention that this solenoid has many winds over many layers. The thickness of the windings is 2.4 inches coming off of the engineering...
- More from Physics Forums - Classical Physics
More news stories
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Alzheimer's disease & dementia 7 hours ago | 5 / 5 (4) | 0 |
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Alzheimer's disease & dementia 9 hours ago | not rated yet | 0 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Alzheimer's disease & dementia 9 hours ago | 5 / 5 (1) | 2 |
A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...
Alzheimer's disease & dementia 12 hours ago | not rated yet | 0
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
Alzheimer's disease & dementia May 21, 2013 | 5 / 5 (7) | 0 |
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
5 hours ago | 4.8 / 5 (5) | 0 |
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
11 hours ago | 4.9 / 5 (8) | 0 |
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...
9 hours ago | 5 / 5 (2) | 0 |
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
9 hours ago | not rated yet | 0 |
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
7 hours ago | not rated yet | 0 |
By discovering the new mechanism by which estrogen suppresses lipid synthesis in the liver, UC Irvine endocrinologists have revealed a potential new approach toward treating certain liver diseases.
7 hours ago | not rated yet | 0 |